c 1311 has been researched along with lissamine rhodamine b in 1 studies
| Studies (c 1311) | Trials (c 1311) | Recent Studies (post-2010) (c 1311) | Studies (lissamine rhodamine b) | Trials (lissamine rhodamine b) | Recent Studies (post-2010) (lissamine rhodamine b) |
|---|---|---|---|---|---|
| 52 | 1 | 23 | 527 | 3 | 207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Comijn, E; De Marco, C; Peters, GJ; Tesei, A; Zaffaroni, N; Zoli, W | 1 |
1 other study(ies) available for c 1311 and lissamine rhodamine b
| Article | Year |
|---|---|
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines.
Topics: Aminoacridines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin B; Cyclin B1; Doxorubicin; Drug Therapy, Combination; G2 Phase; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Paclitaxel; Rhodamines; Tumor Cells, Cultured | 2007 |